Sugi Predict

Sugi Predict / Compounds / SCHEMBL2067101

SCHEMBL2067101

SCHEMBL2067101

COc1ncc(Br)cc1NC(C)=O

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 1/20 0.42
▸ ALDH1A1 P00352 4/20 0.42
▸ PIK3C3 Q8NEB9 2/20 0.41
▸ CYP1A2 P05177 1/20 0.40
▸ DYRK1A Q13627 1/20 0.39
▸ DYRK1B Q9Y463 1/20 0.39
▸ ATM Q13315 1/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ PIK3CG P48736 1/20 0.38
▸ MAPT P10636 1/20 0.37
▸ PIK3CA P42336 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9954256 0.86 MAPT (0.39) ALDH1A1MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL1771736 0.82 MEN1 (0.38) MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL21500091 0.81 AAK1 (0.49) PIK3CDALDH1A1CYP1A2DYRK1AMEN1
SCHEMBL29527107 0.81 AAK1 (0.49) PIK3CDALDH1A1CYP1A2DYRK1AMEN1
SCHEMBL15649386 0.79 DEGS1 (0.47) ALDH1A1CYP1A2MAPTSMN1; SMN2
SCHEMBL1759235 0.78 PIK3C3 (0.52) ALDH1A1PIK3C3DYRK1ADYRK1BMEN1
SCHEMBL1433126 0.78 DYRK1A (0.42) ALDH1A1PIK3C3DYRK1ADYRK1BMAPT
SCHEMBL16680219 0.77 CYP1A2 (0.52) CYP1A2ATMMEN1KMT2AMAPT
SCHEMBL856469 0.77 PTK2 (0.41) PIK3CDALDH1A1DYRK1ADYRK1BPIK3CG
SCHEMBL29527481 0.77 L3MBTL1 (0.51) ALDH1A1CYP1A2SMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118480049-A PKMYT1 inhibitor and preparation method and application thereof 南京同诺康医药科技有限公司 2024-08-13 — — CN disclosed
US-20240158415-A1 AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS HIBERCELL INC (US) 2024-05-16 — — US disclosed
EP-4335512-A2 CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS HiberCell, Inc. (US) 2024-03-13 — — EP disclosed
EP-3728217-B1 CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS HIBERCELL INC (US) 2023-11-15 — — EP disclosed
EP-3728217-B1 CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS HIBERCELL INC (US) 2023-11-15 — — EP disclosed
US-11667651-B2 Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors HIBERCELL, INC. (US) 2023-06-06 — — US disclosed
US-11584763-B2 Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors HIBERCELL, INC. (US) 2023-02-21 — — US disclosed
US-11584763-B2 Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors HIBERCELL, INC. (US) 2023-02-21 — — US disclosed
US-11535635-B2 — — 2022-12-27 — — US disclosed
US-11535635-B2 — — 2022-12-27 — — US disclosed
EP-3728228-A1 AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS Ravenna Pharmaceuticals, Inc. (US) 2020-10-28 — — EP disclosed
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2014-01-02 — — US disclosed
US-8476294-B2 1H-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG (CH) 2013-07-02 — — US disclosed
US-8476294-B2 1H-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG (CH) 2013-07-02 — — US disclosed
US-8476294-B2 1H-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG (CH) 2013-07-02 — — US disclosed
EP-2438064-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES Novartis AG (CH) 2012-04-11 — — EP disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 — — US disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 — — US disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 — — US disclosed
WO-2010139731-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2010-12-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158415-A1 AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS PIP5K1B, PIP5K1A, PIP5K1C PIK3CD 15/4885ALDH1A1 4193/4885PIK3C3 225/4885
US-11584763-B2 Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors PIP5K1A, PIP5K1B, PI4KA PIK3CD 15/4885ALDH1A1 4367/4885PIK3C3 149/4885
US-11535635-B2 — PIP5K1A, PI4K2A, PIP5K1B PIK3CD 36/4885ALDH1A1 2851/4885PIK3C3 924/4885
US-11667651-B2 Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors PIP5K1B, PIP5K1A, PIP5K1C PIK3CD 15/4885ALDH1A1 4132/4885PIK3C3 229/4885
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 PIK3CD 83/4885ALDH1A1 2405/4885PIK3C3 515/4885
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 PIK3CD 83/4885ALDH1A1 2405/4885PIK3C3 515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.